You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
人福醫藥(600079.SH):HW091077片獲得藥物臨牀試驗批准通知書
格隆匯 10-26 16:43

格隆匯10月26日丨人福醫藥(600079.SH)公佈,公司全資子公司武漢人福創新藥物研發中心有限公司(簡稱“人福研發中心”)近日收到國家藥品監督管理局核准簽發的HW091077片的《藥物臨牀試驗批准通知書》。

HW091077片臨牀擬用於難治性慢性咳嗽患者。根據2021年發佈的《中國難治性慢性咳嗽的診斷與治療專家共識》,我國的全國多中心慢性咳嗽病因調查顯示,不明原因咳嗽的慢性咳嗽患者比例約為8.4%。由於病因不明或缺乏有效治療措施,難治性慢性咳嗽在治療上很困難,療效多欠佳或因復發使療效不持久。經Insight數據庫統計,目前國內有8家企業研發的治療難治性慢性咳嗽產品已獲批臨牀,國內尚無批准用於治療難治性慢性咳嗽的藥物上市。截至目前該項目累計研發投入約為3700萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account